Which mechanism of action is unique to ezetimibe among the hyperlipidemic agents?

Explanation

## Ezetimibe: Unique Mechanism of Action **Key Point:** Ezetimibe is the only hyperlipidemic agent that selectively inhibits cholesterol absorption at the intestinal brush border, without affecting the synthesis of cholesterol or metabolism of lipoproteins. ### Mechanism of Action Ezetimibe binds to the **Niemann–Pick C1-like 1 (NPC1L1) protein** on the intestinal epithelial cell membrane, which is responsible for cholesterol uptake. By blocking this transporter, ezetimibe reduces intestinal cholesterol absorption by approximately 50%, leading to: 1. Decreased cholesterol delivery to the liver 2. Upregulation of hepatic LDL receptors (compensatory response) 3. Net reduction in plasma LDL cholesterol (15–20%) **High-Yield:** Ezetimibe is the **only selective cholesterol absorption inhibitor** approved for clinical use. It does not affect the absorption of fat-soluble vitamins or triglycerides significantly. **Clinical Pearl:** Ezetimibe is often combined with statins for additive LDL-lowering effect. The combination reduces LDL by ~50% compared to either agent alone, because: - Statins reduce hepatic synthesis - Ezetimibe reduces intestinal absorption - Both mechanisms are complementary **Mnemonic:** **EZ-absorb** — Ezetimibe blocks intestinal absorption (not synthesis). ### Comparison with Other Agents | Drug Class | Target | Effect | | --- | --- | --- | | **Ezetimibe** | **Intestinal NPC1L1 transporter** | **↓ Cholesterol absorption** | | Statins | HMG-CoA reductase | ↓ Cholesterol synthesis | | Fibrates | PPAR-α | ↑ Lipoprotein lipase, ↓ VLDL | | PCSK9 inhibitors | PCSK9 protein | ↑ LDL receptor recycling | | Bile acid sequestrants | Bile acid reabsorption | ↑ Cholesterol catabolism | **Warning:** Do not confuse ezetimibe with statins — statins inhibit the rate-limiting enzyme in cholesterol *synthesis* (HMG-CoA reductase), whereas ezetimibe blocks cholesterol *absorption*.